Skip to main content Skip to main content
Go to homepage
Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

Sucraid® Oral Solution to treat CSID

Sucraid® Oral Solution to treat Congenital Sucrase-Isomaltase Deficiency (CSID)

Description:

For complete details, please visit this study on Clinicaltrials.gov

Interested in participating?
We are currently recruiting
Study Sponsor:

QOL Medical, LLC

Full IRB Study Title:
Evaluation of a 7-Day Therapeutic Trial Dose of Commercial Sucraid® (sacrosidase) Oral Solution for Alleviating Congenital Sucrase-Isomaltase Deficiency (CSID) Symptoms in Pediatric Subjects with Low, Moderate, and Normal Sucrase Levels
IRB Study ID:
2022-037
If you are interested in this study or have questions about your child's eligibility, please contact:

Joann Katz: 330-543-0690

Lead Investigator
Kevin Watson, MD, FAAP

Pediatric Gastroenterologist; Assistant Director, Clinical Informatics, Specialty Systems; Medical Director, Therapy Plans
Pediatric Gastroenterology

Starting Locations:
Career Opportunities
Legal:
Mobile App:

Akron Children's Anywhere:

About Akron Children's

While we are ranked among the best children's hospitals in the country, it's our compassionate approach to treatment that makes us truly exceptional. Through a combination of revolutionary treatments and extraordinary patient experiences, our care does more than heal. It brings the entire family together for emotional support and understanding across multiple locations to reach you in the community where you live. Learn more...

Akron Children's
One Perkins Square, Akron, Ohio 44308-1062
330-543-1000 • webmaster@akronchildrens.org
An Equal Opportunity Employer
Copyright © 2020, Akron Children's. All Rights Reserved.
  • Magnet Recongnition
  • Newsweek: World's Best Hospitals - 2023
  • Newsweek: World's Best Hospitals - Pediatrics 2023

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.